Discover investment opportunities in Top 10 Stocks Under $90 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $90 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 10 Stocks Under $90 using our Smart AI Filter.
9 stocks found for "Top 10 Stocks Under $90"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.02 Risk measure | ±49.1% Price volatility | 40.9 Valuation | 0.00% Annual yield | |||
1.09 Risk measure | ±47.6% Price volatility | 7.6 Valuation | 3.22% Annual yield | |||
1.16 Risk measure | ±85.2% Price volatility | -18.7 Valuation | 0.00% Annual yield | |||
1.15 Risk measure | ±38.4% Price volatility | 18.9 Valuation | 1.46% Annual yield | |||
0.23 Risk measure | ±21.9% Price volatility | 9.2 Valuation | 6.32% Annual yield | |||
1.38 Risk measure | ±50.4% Price volatility | 28.5 Valuation | 0.00% Annual yield | |||
0.51 Risk measure | ±27.1% Price volatility | 14.6 Valuation | 1.52% Annual yield | |||
0.31 Risk measure | ±21.0% Price volatility | 36.2 Valuation | 0.95% Annual yield | |||
0.49 Risk measure | ±26.2% Price volatility | 25.0 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How does Walmart (WMT) perform in terms of dividend yield compared to other stocks under $90?
A: Walmart (WMT) is known for its stable dividend payments, with a yield lower than some high-dividend stocks but indicative of its consistent performance. Investors view WMT's dividend as steady due to its market position, despite variations in yield compared to more aggressive dividend payers.
Q: What growth prospects does Twilio (TWLO) offer within the tech industry?
A: Twilio (TWLO) has positioned itself uniquely by offering communication infrastructure to developers, a sector poised to grow with digital transformation. TWLO's innovative API solutions have historically driven its growth, but investors should monitor industry competition and TWLO's ability to maintain its tech edge.
Q: Why might investors consider DexCom (DXCM) for their portfolios?
A: DexCom (DXCM), prominent in the diabetes management sector with its glucose monitoring systems, offers growth potential due to rising diabetes prevalence. Investors see value in its innovative products and consistent market demand, though they should assess competitive pressures and product adoption rates.
Q: How does JD.com (JD) navigate the e-commerce sector's challenges?
A: JD.com (JD) leverages its logistics network and technology to enhance user experience, which can be advantageous in the competitive e-commerce market. However, investors should note the risks of regulatory changes in China and online retail saturation.
Q: What stability benefits does Verizon (VZ) offer to investors?
A: Verizon (VZ), a leading telecom provider, offers potential stability through its established network and steady revenue streams. While competition and technology evolution affect the sector, VZ's scale and customer base can provide a cushion against volatility.
Q: What market opportunities might Viking Therapeutics (VKTX) investors explore?
A: Viking Therapeutics (VKTX), focused on metabolic and endocrine disorders therapies, presents a possible growth avenue through its clinical pipeline. Biotech volatility and drug approval processes mean investors must consider trial results and regulatory paths.
The de minimis exemption, which allowed shipments valued under $800 to enter the country duty free, came to an end globally on Friday. The provision had been slated to end in July of 2027 but an executive order from President Trump eliminated it much sooner, giving businesses, customs officials and postal services less time to prepare.
Read more